OMIC

Singular Genomics Systems, Inc. [OMIC] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

OMIC Stock Summary

Top OMIC Correlated Resources

OMIC


Top 10 Correlated ETFs

OMIC


Top 10 Correlated Stocks

OMIC


In the News

09:10 20 Feb 2024 OMIC

Singular Genomics Systems, Inc. (OMIC) Q3 2023 Earnings Call Transcript

Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - CEO, Founder & Chairman Dalen Meeter - CFO Conference Call Participants Dan Brennan - TD Cowen Matt Sykes - Goldman Sachs John Sourbeer - UBS Operator Greetings. Welcome to the Singular Genomics Systems, Inc. Third Quarter 2023 Earnings Conference Call.

04:22 20 Feb 2024 OMIC

Singular Genomics to Report Third Quarter 2023 Financial Results on November 14, 2023

SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the third quarter 2023 after the market close on Tuesday, November 14, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

11:28 20 Feb 2024 OMIC

Beware! 3 Biotech Stocks Waving Massive Red Flags Right Now

The biotech sector never fails to offer up stocks full of massive issues at any given time. Developing novel therapeutic devices and pharmaceuticals is, after all, very expensive.

08:00 20 Feb 2024 OMIC

Singular Genomics to Present at the Gilmartin Group Emerging Growth Company Showcase

SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to participate in the virtual Gilmartin Group Emerging Growth Company Showcase.

08:27 20 Feb 2024 OMIC

Singular Genomics Systems, Inc. (OMIC) Q2 2023 Earnings Call Transcript

Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - Founder, Chair and CEO Dalen Meeter - CFO Conference Call Participants Matt Sykes - Goldman Sachs Dan Brennan - TD Cowen Operator Good day, everyone, and welcome to the Singular Genomics Systems, Inc. Second Quarter 2023 Earnings Conference Call. At this time, all participants have been placed on a listen-only mode, and we will open the floor for your questions and comments after the presentation.

04:05 20 Feb 2024 OMIC

Singular Genomics to Report Second Quarter 2023 Financial Results on August 9, 2023

SAN DIEGO, July 26, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the second quarter 2023 after the market close on Wednesday, August 9, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

04:05 20 Feb 2024 OMIC

Singular Genomics to Present at the Goldman Sachs Global Healthcare Conference

SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA.

06:28 20 Feb 2024 OMIC

Singular Genomics Systems, Inc. (OMIC) Q1 2023 Earnings Call Transcript

Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - Founder and CEO Dalen Meeter - CFO Conference Call Participants Tom Stevens - TD Cowen John Sourbeer - UBS Michael Ryskin - Bank of America Operator Greetings. Welcome to the Singular Genomics Systems, Incorporated First Quarter 2023 Earnings Conference Call.

07:07 20 Feb 2024 OMIC

Similar Genomics Systems (OMIC) Reports Q1 Loss, Lags Revenue Estimates

Similar Genomics Systems (OMIC) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.31 per share a year ago.

04:05 20 Feb 2024 OMIC

Singular Genomics to Report First Quarter 2023 Financial Results on May 9, 2023

SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the first quarter 2023 after the market close on Tuesday, May 9, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

OMIC Financial details

Company Rating
Neutral
Market Cap
40.17M
Income
-89.76M
Revenue
2.6M
Book val./share
2.72
Cash/share
2.61
Dividend
-
Dividend %
-
Employees
284
Optionable
No
Shortable
Yes
Earnings
02 Mar 2024
P/E
-0.36
Forward P/E
-0.43
PEG
0.09
P/S
12.45
P/B
0.16
P/C
0.2
P/FCF
-0.42
Quick Ratio
12.56
Current Ratio
13.64
Debt / Equity
0.39
LT Debt / Equity
0.35
-
-
EPS (TTM)
-1.24
EPS next Y
-1.22
EPS next Q
1.58
EPS this Y
-40.95%
EPS next Y
-1.73%
EPS next 5Y
-1.73%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-8.51%
EPS Q/Q
-11.43%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
34.46%
Inst Trans
0.76%
ROA
-32%
ROE
-39%
ROC
-0.37%
Gross Margin
-5%
Oper. Margin
-3855%
Profit Margin
-3459%
Payout
-
Shs Outstand
73.38M
Shs Float
41.91M
-
-
-
-
Target Price
-
52W Range
0.31-2.515
52W High
-
52W Low
-
RSI
56
Rel Volume
0.48
Avg Volume
182.54K
Volume
88.24K
Perf Week
-5.54%
Perf Month
21.3%
Perf Quarter
12.55%
Perf Half Y
5.69%
-
-
-
-
Beta
1.327
-
-
Volatility
0.02%, 0.06%
Prev Close
-3.36%
Price
0.529
Change
1.63%

OMIC Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K
Revenue per share
0000.01
Net income per share
-0.25-0.41-2.1-1.24
Operating cash flow per share
-0.23-0.36-1.1-1.22
Free cash flow per share
-0.25-0.38-1.2-1.31
Cash per share
0.940.397.213.44
Book value per share
-0.5-0.747.153.66
Tangible book value per share
-0.5-0.747.153.66
Share holders equity per share
-0.5-0.747.153.66
Interest debt per share
0.050.150.230.84
Market cap
1.27B1.78B543.59M143.01M
Enterprise value
1.27B1.78B352.44M127.59M
P/E ratio
-102.96-62.26-5.5-1.62
Price to sales ratio
000186.94
POCF ratio
-111.47-71.75-10.51-1.64
PFCF ratio
-104.16-67.97-9.61-1.54
P/B Ratio
-51.39-34.611.620.55
PTB ratio
-51.39-34.611.620.55
EV to sales
000166.78
Enterprise value over EBITDA
-106.01-67.53-5.82-1.42
EV to operating cash flow
-111.2-71.65-6.82-1.46
EV to free cash flow
-103.9-67.89-6.23-1.37
Earnings yield
-0.01-0.02-0.18-0.62
Free cash flow yield
-0.01-0.01-0.1-0.65
Debt to equity
-0.1-0.180.030.23
Debt to assets
0.050.310.030.18
Net debt to EBITDA
0.260.093.160.17
Current ratio
41.787.4751.5719.01
Interest coverage
-751.18-38.35-72.43-122.53
Income quality
0.920.890.520.96
Dividend Yield
000.010
Payout ratio
00-0.040
Sales general and administrative to revenue
0000
Research and developement to revenue
00060.39
Intangibles to total assets
0000
Capex to operating cash flow
0.070.060.090.07
Capex to revenue
000-7.87
Capex to depreciation
-2.29-2.16-4.29-1
Stock based compensation to revenue
00017.87
Graham number
1.682.6318.3910.11
ROIC
0.570.67-0.18-0.25
Return on tangible assets
-0.26-0.94-0.28-0.27
Graham Net
-0.54-0.796.852.62
Working capital
45.35M23.88M341.02M254.31M
Tangible asset value
-24.73M-51.56M336.17M260.32M
Net current asset value
-26.44M-54.49M328.29M200.78M
Invested capital
-0.1-0.180.030.23
Average receivables
00525K981.5K
Average payables
0494K1.39M2.72M
Average inventory
001.51M10.62M
Days sales outstanding
000435.61
Days payables outstanding
0001.43K
Days of inventory on hand
0008.43K
Receivables turnover
0000.84
Payables turnover
0000.25
Inventory turnover
0000.04
ROE
0.50.56-0.29-0.34
Capex per share
-0.02-0.02-0.1-0.08

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00.010.010.010.01
Net income per share
-0.32-0.27-0.31-0.35-0.31
Operating cash flow per share
-0.31-0.28-0.25-0.28-0.23
Free cash flow per share
-0.32-0.3-0.25-0.28-0.23
Cash per share
3.73.423.142.852.61
Book value per share
3.893.643.343.012.72
Tangible book value per share
3.893.643.343.012.72
Share holders equity per share
3.893.643.343.012.72
Interest debt per share
0.830.830.820.811.06
Market cap
178.04M143.89M87.03M60.18M27.88M
Enterprise value
143.83M128.46M16.35M43.76M71.59M
P/E ratio
-1.94-1.83-0.98-0.59-0.31
Price to sales ratio
0188.09100.85119.1760.35
POCF ratio
-8.17-7.22-4.85-3.01-1.66
PFCF ratio
-7.77-6.62-4.81-2.96-1.65
P/B Ratio
0.640.550.360.280.14
PTB ratio
0.640.550.360.280.14
EV to sales
0167.9318.9586.65154.95
Enterprise value over EBITDA
-6.56-6.16-0.76-1.87-3.54
EV to operating cash flow
-6.6-6.45-0.91-2.19-4.26
EV to free cash flow
-6.28-5.91-0.9-2.16-4.23
Earnings yield
-0.13-0.14-0.25-0.43-0.8
Free cash flow yield
-0.13-0.15-0.21-0.34-0.61
Debt to equity
0.210.230.240.270.39
Debt to assets
0.170.180.190.210.27
Net debt to EBITDA
1.560.743.280.7-2.16
Current ratio
20.1819.0119.7316.1813.64
Interest coverage
-117.03-92.72-97.98-102.23-86.1
Income quality
0.920.940.760.780.75
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
030.79000
Research and developement to revenue
014.0714.172524.29
Intangibles to total assets
00000
Capex to operating cash flow
0.050.090.010.020.01
Capex to revenue
0-2.38-0.19-0.61-0.24
Capex to depreciation
-0.68-1.06-0.09-0.16-0.06
Stock based compensation to revenue
04.053.575.636.05
Graham number
5.34.744.814.894.32
ROIC
-0.06-0.06-0.07-0.09-0.08
Return on tangible assets
-0.07-0.06-0.07-0.09-0.08
Graham Net
2.872.612.362.051.56
Working capital
271.94M254.31M233.98M211.74M195.34M
Tangible asset value
276.93M260.32M240.33M218.39M199.03M
Net current asset value
217.56M200.78M181.33M160.1M125.3M
Invested capital
0.210.230.240.270.39
Average receivables
911K891K779.5K671.5K2.01M
Average payables
3.5M3.04M2.54M1.98M2.2M
Average inventory
14.46M17.46M17.69M15.76M13.89M
Days sales outstanding
0107.4167.37124.22648.9
Days payables outstanding
0353.5220.48297.59415.33
Days of inventory on hand
02.08K1.91K2.16K2.29K
Receivables turnover
00.841.340.720.14
Payables turnover
00.250.410.30.22
Inventory turnover
00.040.050.040.04
ROE
-0.08-0.08-0.09-0.12-0.11
Capex per share
-0.02-0.03000

OMIC Frequently Asked Questions

What is Singular Genomics Systems, Inc. stock symbol ?

Singular Genomics Systems, Inc. is a US stock , located in La jolla of Ca and trading under the symbol OMIC

What is Singular Genomics Systems, Inc. stock quote today ?

Singular Genomics Systems, Inc. stock price is $0.529 today.

Is Singular Genomics Systems, Inc. stock public?

Yes, Singular Genomics Systems, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap